Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?
OBJECTIVE
To review the literature relating to immunosuppressant drug measurement as performed in therapeutic drug monitoring laboratories associated with transplantation centers and consider whether the assay methods widely used for patient dosage management achieve acceptable quality criteria in the context of other sources of variability with these drugs.


METHODS
Articles used were accessed primarily through MEDLINE, as well as references cited in related publications. Searches were restricted to organ transplantation in humans.


METHODS
Emphasis was placed on the literature relating to the quality of immunosuppressant drug assays, their limitations, and evidence of clinical benefit in dosage individualization.


RESULTS
There is a dilemma evident between the quality of the analytical services offered by some diagnostic immunoassay manufacturers and the ability of a significant number of clinical laboratories globally to select only appropriate assay methods.


CONCLUSIONS
In many cases, clinical laboratories fail to meet the reasonable clinical expectations required for interpretation of immunosuppressant drug assay results as an adjunct to optimal dosage individualization and patient care.
Morris
Raymond G
RG
Clinical Pharmacology Laboratory, The Queen Elizabeth Hospital, Woodville SA, Australia.
D016572:Cyclosporine / Q000097:blood; D016903:Drug Monitoring / Q000592:standards*; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D007753:Laboratories / Q000592:standards*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000097:blood; D011786:Quality Control; D020123:Sirolimus / Q000097:blood; D016559:Tacrolimus / Q000097:blood; D014180:Transplantation
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus